Company profile
Obsidian Therapeutics, Inc.
OBX · Nasdaq (Went public via reverse merger into Nasdaq-listed Galera Therapeutics with a $350M private placement; began trading as OBX on 4 Aug 2026. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.fiercebiotech.com/biotech/cell-therapy-biotech-obsidian-leverages-galera-reverse-merger-go-public]) · United States
Share price · OBX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IL-15 receptor signalingBiologic — subtype unspecified | Non-Small Cell Lung Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.